Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Antibody–drug conjugates (ADCs) and next-generation antibody conjugates have rapidly become a leading class of targeted biologics, combining the molecular specificity of antibodies with highly potent payloads. With multiple global approvals and a fast-expanding clinical pipeline, ADCs are reshaping therapeutic strategies across oncology and immune-related diseases.
Unlike conventional monoclonal antibodies, ADCs are inherently multi-component systems. Their clinical performance is governed by the integrated control of antibody engineering, linker–payload chemistry, conjugation strategy, and manufacturing process consistency. Small variations in conjugation or process conditions can significantly affect drug-to-antibody ratio (DAR), stability, pharmacokinetics, and safety.
As the field advances toward site-specific conjugation technologies and next-generation antibody conjugates, regulatory expectations increasingly emphasize process understanding, critical quality attribute control, and CMC readiness. Successful ADC translation, therefore, depends on early, end-to-end integration of biologics, chemistry, analytics, and GMP-aligned manufacturing—making an experienced, cross-disciplinary CDMO partner essential.
Creative Biogene provides an integrated ADC platform covering antibody generation, linker–payload development, bioconjugation process engineering, GMP manufacturing, and pharmacodynamic evaluation. Our platform is designed to support both classical ADCs and emerging conjugate modalities within a unified quality and regulatory framework.
Creative Biogene offers end-to-end ADC CDMO services from payload–linker synthesis to drug substance and drug product manufacturing, enabling seamless technology transfer and reduced development risk across discovery, IND-enabling, clinical, and commercial stages.
CMC & GMP Manufacturing

Linker–Payload Platform

Antibody & Cell Platform

Analytics & Translation

Conjugation Platform

Our ADC platform integrates multidisciplinary expertise across chemistry, biologics, analytics and regulatory sciences.
High-quality conjugates start with developable antibodies. Our biologics platform integrates antibody engineering with downstream conjugation strategy design.
Capabilities

Creative Biogene provides in-house linker–payload development and high-potency manufacturing infrastructure to support scalable ADC production.
capabilities

Our conjugation platform is designed for reproducibility, DAR control, and regulatory-ready scale-up.
Process and manufacturing features:

Creative Biogene operates a dedicated ADC analytical platform aligned with ICH Q6B, Q1A–Q1E and emerging FDA / EMA ADC guidance.
Molecular Characterization
Impurity & Safety Profiling
Sterility & Container Integrity
Stability & Formulation
| Test Category | Capability |
| Intact mass analysis | LC-MS, accuracy < 5 ppm |
| DAR determination | HIC, RP-LC, LC-MS (±0.2 precision) |
| Conjugation site mapping | LC-MS/MS |
| Aggregation & purity | SEC-HPLC, CE-SDS |
| Higher-order structure | CD, FT-IR, DSC (Tm ±0.5 °C) |
| Category | Control Capability |
| Free payload | LOQ ≤ 0.05% |
| Genotoxic impurities | ICH M7 compliant, LC-MS/MS |
| Residual solvents | USP<467>, GC-MS |
| Unconjugated antibody | HIC ≤ 1% |
| Test | Capability |
| Endotoxin | LOD ≤ 0.01 EU/mL |
| Sterility | Isolator-based sterility testing |
| CCI testing | Vacuum decay, ≥ 1 μm sensitivity |
| Study Type | Capability |
| Forced degradation | Oxidation, heat, pH, light, freeze–thaw |
| Long-term stability | 2–8 °C, up to 24 months |
| Formulation | Liquid and lyophilized |
| Transport simulation | Agitation and vibration stress |
Creative Biogene offers dedicated development and manufacturing platforms tailored to different conjugate modalities and development stages.
With integrated chemistry, biologics, analytics, and regulatory infrastructure, Creative Biogene delivers development-ready conjugates with controlled quality, scalable processes, and regulatory confidence. Our ADC CDMO platform supports flexible collaboration models:
Programs may enter at any development stage while maintaining continuity toward GMP manufacturing and regulatory submission. Contact our ADC CDMO team to discuss your program requirements and development strategy.
Copyright © Creative Biogene. All rights reserved.



